Association of Amyloid Reduction After Donanemab Treatment With Tau Pathology and Clinical Outcomes: The TRAILBLAZER-ALZ Randomized Clinical Trial.
Saved in:
| Title: | Association of Amyloid Reduction After Donanemab Treatment With Tau Pathology and Clinical Outcomes: The TRAILBLAZER-ALZ Randomized Clinical Trial. |
|---|---|
| Authors: | Shcherbinin S; Eli Lilly and Company, Indianapolis, Indiana., Evans CD; Eli Lilly and Company, Indianapolis, Indiana., Lu M; Eli Lilly and Company, Indianapolis, Indiana.; Avid Radiopharmaceuticals, a wholly owned subsidiary of Eli Lilly and Company, Philadelphia, Pennsylvania., Andersen SW; Eli Lilly and Company, Indianapolis, Indiana., Pontecorvo MJ; Eli Lilly and Company, Indianapolis, Indiana.; Avid Radiopharmaceuticals, a wholly owned subsidiary of Eli Lilly and Company, Philadelphia, Pennsylvania., Willis BA; Eli Lilly and Company, Indianapolis, Indiana.; Now with Eisai Inc, Nutley, New Jersey., Gueorguieva I; Eli Lilly and Company, Indianapolis, Indiana., Hauck PM; Eli Lilly and Company, Indianapolis, Indiana., Brooks DA; Eli Lilly and Company, Indianapolis, Indiana., Mintun MA; Eli Lilly and Company, Indianapolis, Indiana.; Avid Radiopharmaceuticals, a wholly owned subsidiary of Eli Lilly and Company, Philadelphia, Pennsylvania., Sims JR; Eli Lilly and Company, Indianapolis, Indiana. |
| Source: | JAMA neurology [JAMA Neurol] 2022 Oct 01; Vol. 79 (10), pp. 1015-1024. |
| Publication Type: | Clinical Trial, Phase II; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't |
| Journal Info: | Publisher: American Medical Association Country of Publication: United States NLM ID: 101589536 Publication Model: Print Cited Medium: Internet ISSN: 2168-6157 (Electronic) Linking ISSN: 21686149 NLM ISO Abbreviation: JAMA Neurol Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 2168-6157 |
|---|---|
| DOI: | 10.1001/jamaneurol.2022.2793 |
